Fig. 4

Preferential elimination of MCL-ICs by inhibition of Wnt signaling. a Percentage of MCL-ICs evaluated by immunostaining and flow cytometry (as shown in Fig. 1a) of primary MCL cells (n = 3) treated with vincristine (5 nM), doxorubicin (35 nM), or ibrutinib (10 μM), the Wnt inhibitors, CCT036477 (10 μM), iCRT14 (10 μM), or PKF118-310 (10 μM), for 48 h. *Differences between treated and control group were significant P < 0.05 (b–c) qRT-PCR analysis of the expression of (b) Wnt target genes encoding PPARδ, Cyclin D1, Myc, TCF4, ID2, and (c) stem cell core transcription factors Nanog, Oct4, Myc, Sox2, and Klf4 in MCL-ICs (n = 3) treated with 10 μM CCT036477 for 6 h. Gli2 is an off-target control. *P < 0.05